Nesvacumab

• Description :

  Nesvacumab is a fully human immunoglobulin G1 (IgG1) monoclonal antibody that specifically binds and inactivates the Tie2 receptor ligand Angiopoietin-2 (Ang2) with high affinity, but shows no binding to Ang1. Nesvacumab can be used in vascular researches[1][2].

• UNSPSC :

  12352203

• Target :

  Tie

• Type :

  Inhibitory Antibodies

• Related Pathways :

  Protein Tyrosine Kinase/RTK

• Applications :

  COVID-19-immunoregulation

• Field of Research :

  Inflammation/Immunology; Cardiovascular Disease; Cancer

• Assay Protocol :

  https://www.medchemexpress.com/nesvacumab.html

• Purity :

  99.11

• Solubility :

  H2O

• Smiles :

  [Nesvacumab]

• Molecular Weight :

  (144.86 kDa)

• References & Citations :

  [1]Kyriakos P Papadopoulos, et al. A Phase I First-in-Human Study of Nesvacumab (REGN910), a Fully Human Anti-Angiopoietin-2 (Ang2) Monoclonal Antibody, in Patients with Advanced Solid Tumors. Clin Cancer Res. 2016 Mar 15;22 (6) :1348-55.|[2]Vakili S, et al. Angiopoietin-2 reverses endothelial cell dysfunction in progeria vasculature. Aging Cell. 2025 Feb;24 (2) :e14375.

• Shipping Conditions :

  Dry Ice

• Storage Conditions :

  Store at -80°C for 2 years

• Scientific Category :

  Inhibitory Antibodies

• Clinical Information :

  Phase 1

• CAS Number :

  [1296818-77-3]